The PreCePra phase 3 trial demonstrates that high CNS pain activation on fMRI predicts a better clinical response to TNF inhibition in rheumatoid arthritis (RA).
Patients with high disease-associated brain activation had a significantly higher rate of achieving low disease activity after 12 weeks of certolizumab pegol treatment.
This study provides a potential objective biomarker for guiding biologic therapy in RA, addressing the challenge of subjective response metrics.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.